192 related articles for article (PubMed ID: 8342267)
21. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
[TBL] [Abstract][Full Text] [Related]
22. Antiplatelet and lipid-lowering therapies for the secondary prevention of cardiovascular disease: are we doing enough?
Xhignesse M; Laplante P; Grant AM; Niyonsenga T; Delisle E; Vanasse N; Bernier R
Can J Cardiol; 1999 Feb; 15(2):185-9. PubMed ID: 10079778
[TBL] [Abstract][Full Text] [Related]
23. [Therapeutic measures following acute myocardial infarct: differential use of PTCA, surgery and drugs].
Noll G; Kaufmann U; Wenzel RR; Lüscher TF
Schweiz Med Wochenschr; 1996 Feb; 126(5):164-76. PubMed ID: 8685687
[TBL] [Abstract][Full Text] [Related]
24. Combination antiplatelet agents for secondary prevention of ischemic stroke.
Vande Griend JP; Saseen JJ
Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
[TBL] [Abstract][Full Text] [Related]
25. Critical pathways using platelet testing to potentially optimize the use of oral antiplatelet therapy.
Cannon CP; McLean DS
Am J Cardiol; 2006 Nov; 98(10A):33N-38N. PubMed ID: 17097416
[TBL] [Abstract][Full Text] [Related]
26. Antiplatelet therapy in patients with unstable angina and non-ST-segment-elevation myocardial infarction: findings from the CRUSADE national quality improvement initiative.
Bottorff MB; Nutescu EA; Spinler S
Pharmacotherapy; 2007 Aug; 27(8):1145-62. PubMed ID: 17655514
[TBL] [Abstract][Full Text] [Related]
27. Antiplatelet therapy and cardiovascular primary prevention: influence of gender, age and other risk factors.
Sousa CS; Fonseca T; Clara JG
Rev Port Cardiol; 2008 Apr; 27(4):513-27. PubMed ID: 18605070
[TBL] [Abstract][Full Text] [Related]
28. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
[TBL] [Abstract][Full Text] [Related]
30. Combination antiplatelet agents in ischemic cerebrovascular disease.
Moussouttas M; Papamitsakis N
Mt Sinai J Med; 2005 Jan; 72(1):16-22. PubMed ID: 15682258
[TBL] [Abstract][Full Text] [Related]
31. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.
Fox KA; Mehta SR; Peters R; Zhao F; Lakkis N; Gersh BJ; Yusuf S;
Circulation; 2004 Sep; 110(10):1202-8. PubMed ID: 15313956
[TBL] [Abstract][Full Text] [Related]
32. Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.
Savonitto S; Ambrosini V; Marzocchi A; Tolaro S; Petronio AS; Galassi AR; Bongo AS; Gaglione A; Bolognese L; ;
Ital Heart J; 2005 Feb; 6(2):106-18. PubMed ID: 15819503
[TBL] [Abstract][Full Text] [Related]
33. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Bhatt DL; Topol EJ;
Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995
[TBL] [Abstract][Full Text] [Related]
34. The use of antithrombotic drugs in older people.
Tufano A; Cerbone AM; Di Minno G
Minerva Med; 2002 Feb; 93(1):13-26. PubMed ID: 11850611
[TBL] [Abstract][Full Text] [Related]
35. Clinical use of antiplatelet therapy.
Balsano F; Violi F
Haematologica; 1989; 74(3):325-9. PubMed ID: 2511106
[TBL] [Abstract][Full Text] [Related]
36. Antiplatelet therapy in cardiovascular disease.
Ahmed SM; O'Leary EL; Innone LA
Compr Ther; 2010; 36():20-2. PubMed ID: 21229816
[TBL] [Abstract][Full Text] [Related]
37. Antiplatelet drugs in secondary prevention of myocardial infarction: clinical recommendations and perspective implications.
Libretti A; Bertelé V
J Cardiovasc Pharmacol; 1989; 14 Suppl 9():S89-91. PubMed ID: 2483241
[TBL] [Abstract][Full Text] [Related]
38. New players in the field of antiplatelet and anticoagulant therapy in coronary heart disease - current therapeutic issues and hot topics.
Schindler C
Ther Adv Cardiovasc Dis; 2009 Dec; 3(6):413-21. PubMed ID: 19917636
[No Abstract] [Full Text] [Related]
39. The Role of Antiplatelet Therapy in Primary Prevention. A Review.
Ostergaard L; Fosbol EL; Roe MT
Curr Pharm Des; 2017; 23(9):1294-1306. PubMed ID: 27917712
[TBL] [Abstract][Full Text] [Related]
40. Platelet inhibitor agents in cardiovascular disease: an update.
Stein B; Fuster V; Israel DH; Cohen M; Badimon L; Badimon JJ; Chesebro JH
J Am Coll Cardiol; 1989 Oct; 14(4):813-36. PubMed ID: 2677086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
